Citations

Clear

4610 citation(s) found for "Lu, Brian".

A Discrete Event Simulation Model to Evaluate Operational Performance of a Colonoscopy Suite
Berg, Bjorn P. , Nelson, Heidi , Balasubramanian, Hari , Rahman, Ahmed S. , Bailey, Angela , Lindor, Keith D. , Denton, Brian T.

Mayo Clinic

Medical Decision Making | September 22, 2009 | Volume: 30 | Issue: 3 | Pages: 380-387

10.1177/0272989x09345890 | PMID 19773583 Get It

Background and Aims. Colorectal cancer, a leading cause of cancer death, is preventable with colonoscopic screening. Colonoscopy cost is high, and optimizing resource utilization for colonoscopy is important. This study’s aim is to evaluate resource allocation for optimal use of facilities for colonoscopy screening. Method. The authors used data from a computerized colonoscopy database to develop a discrete event simulation model of a colonoscopy suite. Operational configurations were compared by varying the number of endoscopists, procedure rooms, the patient arrival times, and procedure room turnaround time. Performance measures included the number of patients served during the clinic day and utilization of key resources. Further analysis included considering patient waiting time tradeoffs as well as the sensitivity of the system to procedure room turnaround time. Results. The maximum number of patients served is linearly related to the number of procedure rooms in the colonoscopy suite, with a fixed room to endoscopist ratio. Utilization of intake and recovery resources becomes more efficient as the number of procedure rooms increases, indicating the potential benefits of large colonoscopy suites. Procedure room turnaround time has a significant influence on patient throughput, procedure room utilization, and endoscopist utilization for varying ratios between 1:1 and 2:1 rooms per endoscopist. Finally, changes in the patient arrival schedule can reduce patient waiting time while not requiring a longer clinic day. Conclusions. Suite managers should keep a procedure room to endoscopist ratio between 1:1 and 2:1 while considering the utilization of related key resources as a decision factor as well. The sensitivity of the system to processes such as turnaround time should be evaluated before improvement efforts are made.
A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials of DHEA Treatment Effects on Quality of Life in Women with Adrenal Insufficiency
Alkatib, Aziz A., Cosma, Mihaela, Elamin, Mohamed B., Erickson, Dana , Swiglo, Brian A., Erwin, Patricia J., Montori, Víctor M. , Montori, Victor M

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 22, 2009 | Volume: 94 | Issue: 10 | Pages: 3676-3681

10.1210/jc.2009-0672 | PMID 19773400 Get It

Functional and Clinical Significance of Variants Localized to 8q24 in Colon Cancer
Cicek, Mine , Achenbach, Sara J., French, Amy J. , Blair, Hilary, Fink, Stephanie, Foster, Nathan R. , Kabat, Brian, Halling, Kevin C. , Cunningham, Julie M. , Cerhan, James R. , Jenkins, Robert B. , Boardman, Lisa A., Petersen, Gloria M. , Sargent, Daniel J. , Thibodeau, Stephen N. , Slager, Susan L. , Boardman, Lisa A., Alberts, Steven R. , Limburg, Paul J. , Sargent, Daniel J , Cerhan, James R

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 11, 2009 | Volume: 18 | Issue: 9 | Pages: 2492-2500

10.1158/1055-9965.epi-09-0362 | PMID 19690179 Get It

Abstract Multiple genome-wide association studies have identified several susceptibility variants for colon cancer at 8q24. However, the functional roles of these variants have yet to be elucidated. Here, we evaluated the potential role of these markers in tumor progression and examined association with commonly observed structural abnormalities in this region, c-MYC amplification and chromosome fragility at FRA8C and FRA8D. We first replicated the previously reported association by testing 1,178 cases and 1,009 clinic-based controls with eight markers localized to three specific regions at 8q24. We observed significant associations with colon cancer risk with markers rs13254738 (ordinal odds ratio, 0.82; 95% confidence interval, 0.072-0.94; Ptrend = 0.0037) and rs6983267 (ordinal odds ratio, 1.17; 95% confidence interval, 1.03-1.32, Ptrend = 0.013). Survival analysis was done using a separate set of 460 cases to evaluate the clinical significance of these markers. Overall, univariate analysis did not detect survival differences for any of the markers. We also tested a subset of the 460 cases (n = 380) for structural abnormalities at or near the c-MYC locus using fluorescence in situ hybridization analysis. Furthermore, we evaluated a small number of cases homozygous for the rs6983267 alleles to test for differences in fragile site induction. None of the 8q markers correlated with amplification at the c-MYC locus as detected by fluorescence in situ hybridization, and no clear pattern of breakage was observed at the FRA8C and FRA8D sites. In this study, we confirm the association for several single nucleotide polymorphisms at 8q24 in colon cancer but have not detected any structural role relating to c-MYC amplification or chromosomal fragility. Finally, these risk alleles do not seem to be associated with survival. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2492–500)
Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for P
Micallef, Ivana N. , Stiff, Patrick J. , Bolwell, Brian J., Jacobsen, Eric D. , Nademanee, Auayporn, McCarty, John M. , Bridger, Gary, Calandra, Gary, DiPersio, John F. , Maziarz, Richard Thomas

Mayo Clinic

Journal of Clinical Oncology | August 31, 2009 | Volume: 27 | Issue: 28 | Pages: 4767-4773

10.1200/jco.2008.20.7209 | PMID 19720922 Get It

Purpose This study evaluates the safety and efficacy of plerixafor (AMD3100), a CXCR4 antagonist, in mobilizing hematopoietic stem cells for autologous stem-cell transplantation in non-Hodgkin's lymphoma (NHL) patients. Patients and Methods This is a phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study. Patients with non-Hodgkin's lymphoma requiring an autologous hematopoietic stem-cell transplantation in first or second complete or partial remission were eligible. Patients received granulocyte colony-stimulating factor (G-CSF; 10 μg/kg) subcutaneously daily for up to 8 days. Beginning on evening of day 4 and continuing daily for up to 4 days, patients received either plerixafor (240 μg/kg) or placebo subcutaneously. Starting on day 5, patients began daily apheresis for up to 4 days or until ≥ 5 × 10 6 CD34+ cells/kg were collected. The primary end point was the percentage of patients who collected ≥ 5 × 10 6 CD34+ cells/kg in 4 or fewer apheresis days. Results This report presents all data for all patients (n = 298) through 12 months follow-up. Eighty-nine (59%) of 150 patients in the plerixafor group and 29 (20%) of 148 patients in the placebo group met the primary end point (P < .001). One hundred thirty-five patients (90%) in plerixafor group and 82 patients (55%) in placebo group underwent transplantation after initial mobilization. Median time to engraftment was similar in both groups. The most common plerixafor-associated adverse events were GI disorders and injection site reactions. Conclusion Plerixafor and G-CSF were well tolerated and resulted in a significantly higher proportion of patients with non-Hodgkin's lymphoma achieving the optimal CD34+ cell target for transplantation in fewer apheresis days, compared with G-CSF alone.
Atopic Disease and Risk of Non–Hodgkin Lymphoma: An InterLymph Pooled Analysis
Vajdic, Claire M. , Falster, Michael O. , Sanjosé, Sílvia de, Martı́nez-Maza, Otoniel , Becker, Nikolaus, Bracci, Paige M. , Melbye, Mads , Smedby, Karin E. , Turner, Jennifer , Vineis, Paolo , Costantini, Adele Seniori , Holly, Elizabeth A., Kane, Eleanor , Spinelli, John J., Vecchia, Carlo La , Zheng, Tongzhang, Maso, Luigino Dal , Cocco, Pierluigi , Foretová, Lenka , Staines, Anthony , Brennan, Paul , Severson, Richard K., Cerhan, James R. , Breen, Elizabeth C. , Birmann, Brenda M. , Grulich, Andrew E. , Engels, Eric A. , Chiu, Brian C.‐H. , Maynadié, Marc , Davis, Scott , Cozen, Wendy , Cerhan, James R , Turner, Jennifer , Cocco, Pierluigi , Vajdic, Claire M , Kane, Eleanor , Martínez-Maza, Otoniel , Birmann, Brenda M

Mayo Clinic

Cancer Research | August 5, 2009 | Volume: 69 | Issue: 16 | Pages: 6482-6489

10.1158/0008-5472.can-08-4372 | PMID 19654312 Get It

AbstractWe performed a pooled analysis of data on atopic disease and risk of non–Hodgkin lymphoma (NHL) from 13 case-control studies, including 13,535 NHL cases and 16,388 controls. Self-reported atopic diseases diagnosed 2 years or more before NHL diagnosis (cases) or interview (controls) were analyzed. Pooled odds ratios (OR) and 95% confidence intervals (95% CI) were computed in two-stage random-effects or joint fixed-effects models, and adjusted for age, sex, and study center. When modeled individually, lifetime history of asthma, hay fever, specific allergy (excluding hay fever, asthma, and eczema), and food allergy were associated with a significant reduction in NHL risk, and there was no association for eczema. When each atopic condition was included in the same model, reduced NHL risk was only associated with a history of allergy (OR, 0.80; 95% CI, 0.68–0.94) and reduced B-cell NHL risk was associated with history of hay fever (OR, 0.85; 95% CI, 0.77–0.95) and allergy (OR, 0.84; 95% CI, 0.76–0.93). Significant reductions in B-cell NHL risk were also observed in individuals who were likely to be truly or highly atopic—those with hay fever, allergy, or asthma and at least one other atopic condition over their lifetime. The inverse associations were consistent for the diffuse large B-cell and follicular subtypes. Eczema was positively associated with lymphomas of the skin; misdiagnosis of lymphoma as eczema is likely, but progression of eczema to cutaneous lymphoma cannot be excluded. This pooled study shows evidence of a modest but consistent reduction in the risk of B-cell NHL associated with atopy. [Cancer Res 2009;69(16):6482–9]
Differential effects of insulin deprivation and systemic insulin treatment on plasma protein synthesis in type 1 diabetic people
Jaleel, Abdul , Klaus, Katherine A. , Morse, Dawn M., Karakelides, Helen, Ward, Lawrence E., Irving, Brian A. , Nair, K. Sreekumaran

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | August 5, 2009 | Volume: 297 | Issue: 4 | Pages: E889-E897

10.1152/ajpendo.00351.2009 | PMID 19654285 Get It

It remains to be determined whether systemic insulin replacement normalizes synthesis rates of different plasma proteins and whether there are differential effects on various plasma proteins. We tested a hypothesis that insulin deprivation differentially affects individual plasma protein synthesis and that systemic insulin treatment may not normalize synthesis of all plasma proteins. We measured synthesis rates of 41 plasma proteins in seven each of type 1 diabetic (T1DM) and nondiabetic participants (ND) using [ ring-13C6]phenylalanine as a tracer. T1DM were studied while on chronic insulin treatment and during 8 h insulin deprivation. Insulin treatment normalized glucose levels, but plasma insulin levels were higher during insulin treatment than during insulin deprivation in T1DM and ND. Individual plasma proteins were purified by affinity chromatography and two-dimensional gel electrophoresis. Only 41 protein gel spots from over 300 were chosen based on their protein homogeneity. Insulin deprivation and hyperglycemia either significantly increased ( n = 12) or decreased ( n = 12) synthesis rates of 24 of 41 plasma proteins in T1DM compared with ND. Insulin treatment normalized synthesis rates of 13 of these 24 proteins, which were altered during insulin deprivation. However, insulin treatment significantly altered the synthesis of 14 additional proteins. In conclusion, acute insulin deprivation caused both a decrease and increase in synthesis rates of many plasma proteins with various functions. Moreover, chronic systemic insulin treatment not only did not normalize synthesis of all plasma proteins but also altered synthesis of several additional proteins that were unaltered during insulin deprivation.
Radiation-induced rhabdomyosarcoma of the brainstem in a patient with neurofibromatosis Type 2
Carlson, Matthew L. , Babovic‐Vuksanovic, Dusica , Messiaen, Ludwine , Scheithauer, Bernd W., Neff, Brian A., Link, Michael J.

Mayo Clinic

Journal of Neurosurgery | July 3, 2009 | Volume: 112 | Issue: 1 | Pages: 81-87

10.3171/2009.6.jns09105 | PMID 19575577 Get It

Neurofibromatosis Type 2 (NF2) is a rare autosomal dominant disorder characterized by the development of benign tumors of the peripheral nervous system and the CNS, including schwannomas, meningiomas, and ependymomas. The gene responsible for the development of NF2 acts as a tumor suppressor gene. Stereotactic radiotherapy (SRT) or single-fraction stereotactic radiosurgery has been increasingly used in the past decades to treat benign tumors in patients with NF2. These radiotherapy methods are less invasive and can be potentially used to treat multiple tumors in a single session. The risk of inducing malignancy is unclear. Few reports exist of malignant peripheral nerve sheath tumors, meningiomas, or ependymomas occurring after SRT or stereotactic radiosurgery in patients with NF2. The authors present the first documented case of rhabdomyosarcoma following SRT for multiple NF2-associated schwannomas. Compared with patients with sporadic tumors, NF2 patients having a germline tumor suppressor gene defect may be more prone to secondary malignancies after treatment involving radiation therapy.
Pathways to Approval of Pediatric Cardiac Devices in the United States: Challenges and Solutions
Beekman, Robert H., Duncan, Brian W., Hagler, Donald J. , Jones, Thomas K. , Kugler, John D., Moore, John W. , Jenkins, Kathy J.

Mayo Clinic

Pediatrics | June 29, 2009 | Volume: 124 | Issue: 1 | Pages: e155-e162

10.1542/peds.2008-3726 | PMID 19564262 Get It

Patients treated by pediatric interventional cardiologists and cardiac surgeons often have unmet medical device needs that pose a challenge to the current regulatory evaluation and approval process in the United States. In this report we review current US Food and Drug Administration regulatory processes, review some unique aspects of pediatric cardiology and cardiac surgery that pose challenges to these processes, and discuss possible alternate pathways to cardiac device evaluation and approval for children. Children deserve to benefit from new and refined cardiac devices and technology designed explicitly for their conditions.
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
Kumar, Shaji , Stadtmauer, Edward A. , Harousseau, Jean Luc, Palumbo, Antonio, Bensinger, William, Comenzo, Raymond L. , Lentzsch, Suzanne , Munshi, Nikhil C. , Niesvizky, Rubén, Miguel, Jesús F. San , Bergsagel, Leif, Bladé, Joan , Tosi, Patrizia , Sonneveld, Pieter , Sezer, Orhan , Vesole, David H., Cavo, Michèle , Richardson, Paul G. , Durie, Brian G.M. , Rajkumar, S. Vincent , Bergsagel, P. Leif , Giralt, Sergio , Ludwig, Heinz , Lonial, Sagar , Anderson, Kenneth C. , Einsele, Hermann , Richardson, Paul Gerard Guy , Bergsagel, P. Leif , Rajkumar, S Vincent , San-Miguel, Jesus

Mayo Clinic

Blood | June 27, 2009 | Volume: 114 | Issue: 9 | Pages: 1729-1735

10.1182/blood-2009-04-205013 | PMID 19561323 Get It

The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell transplantation remains an important therapeutic option for patients with multiple myeloma eligible for the procedure. Before the advent of the novel agents, patients underwent stem cell collection prior to significant alkylating agent exposure, given its potential deleterious effect on stem cell collection. With increasing use of the novel agents in the upfront setting, several reports have emerged raising concerns about their impact on the ability to collect stem cells. An expert panel of the International Myeloma Working Group (IMWG) was convened to examine the implications of these therapies on stem collection in patients with myeloma and to develop recommendations for addressing these issues. Here we summarize the currently available data and present our perspective on the problem and potential options to overcome this problem. Specifically, we recommend early mobilization of stem cells, preferably within the first 4 cycles of initial therapy, in patients treated with novel agents and encourage participation in clinical trials evaluating novel approaches to stem cell mobilization.